Zoetis Inc. (NYSE:ZTS) had its price objective upped by analysts at BMO Capital Markets from $65.00 to $70.00 in a report issued on Friday. The firm presently has a “market perform” rating on the stock. BMO Capital Markets’ target price would indicate a potential upside of 1.91% from the company’s previous close.

Other equities analysts have also recently issued research reports about the stock. Stifel Nicolaus reiterated a “buy” rating and issued a $65.00 target price on shares of Zoetis in a research report on Friday, July 21st. Deutsche Bank AG reiterated a “buy” rating and issued a $65.00 target price (up previously from $62.00) on shares of Zoetis in a research report on Monday, July 17th. Cowen and Company set a $70.00 price target on shares of Zoetis and gave the stock a “buy” rating in a report on Monday, July 17th. Cantor Fitzgerald reissued a “buy” rating and issued a $75.00 price target on shares of Zoetis in a report on Wednesday, September 6th. Finally, Piper Jaffray Companies set a $73.00 price target on shares of Zoetis and gave the stock a “buy” rating in a report on Friday, August 25th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and eleven have issued a buy rating to the stock. Zoetis currently has an average rating of “Hold” and an average price target of $66.28.

Shares of Zoetis (NYSE:ZTS) traded up $4.18 during trading hours on Friday, reaching $68.69. 4,320,676 shares of the company were exchanged, compared to its average volume of 2,443,592. The company has a market cap of $32,799.38, a PE ratio of 30.88 and a beta of 1.02.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.02. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 66.15%. The firm’s revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.52 EPS. sell-side analysts forecast that Zoetis will post 2.36 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Zoetis Inc. (ZTS) Price Target Raised to $70.00 at BMO Capital Markets” was first reported by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/11/03/zoetis-inc-zts-price-target-raised-to-70-00-at-bmo-capital-markets.html.

Institutional investors and hedge funds have recently made changes to their positions in the company. Assetmark Inc. boosted its stake in shares of Zoetis by 7.5% during the 3rd quarter. Assetmark Inc. now owns 1,930 shares of the company’s stock valued at $100,000 after purchasing an additional 134 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Zoetis by 16.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after purchasing an additional 230 shares in the last quarter. NEXT Financial Group Inc boosted its stake in shares of Zoetis by 9.5% during the 2nd quarter. NEXT Financial Group Inc now owns 2,136 shares of the company’s stock valued at $101,000 after purchasing an additional 186 shares in the last quarter. Guardian Life Insurance Co. of America boosted its stake in shares of Zoetis by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after purchasing an additional 13 shares in the last quarter. Finally, Point72 Asia Hong Kong Ltd bought a new stake in shares of Zoetis during the 1st quarter valued at about $111,000. 93.04% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.